Skip to main content
CORT
NASDAQ Life Sciences

Stockholders Approve 8 Million Share Increase for Incentive Plan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$68.38
Mkt Cap
$7.341B
52W Low
$28.66
52W High
$91
52W Position info
139% above low
Off High info
25% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CORT has more than doubled off its 52-week low of $28.66.

Summary

Corcept Therapeutics stockholders approved an amendment to the 2024 Incentive Award Plan, increasing the shares available for issuance by 8 million, representing significant potential dilution.


Key Events · Financing and Capital Events · CORT

  • Incentive Plan Share Increase Approved

    Stockholders approved an amendment to the 2024 Incentive Award Plan, increasing the number of shares available for issuance by 8,000,000 shares.

  • Potential Dilution

    If all 8,000,000 newly authorized shares were issued, it would represent a substantial potential dilution, valued at approximately $547 million at the current stock price.

  • Annual Meeting Results

    Other proposals, including the election of directors, ratification of auditors, and advisory approval of executive compensation, were also approved at the Annual Meeting.


Analysis · CORT · Life Sciences

The approval of an additional 8 million shares for the company's incentive award plan represents a substantial potential dilution, valued at approximately $547 million if fully utilized at current prices. While such plans are common for employee retention, this significant increase in authorized shares could weigh on the stock, particularly following recent negative news regarding Q1 earnings and a failed ALS study.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CORT was trading at $68.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $28.66 to $91.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CORT - Latest Insights

CORT
Nov 03, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $78.50
Real-time Price: $69.22 info
Change: -$9.28 (-12%) info
Market Cap: $7.576B info
CORT
Nov 03, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $81.93
Real-time Price: $69.22 info
Change: -$12.71 (-16%) info
Market Cap: $7.576B info
CORT
Oct 26, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $86.01
Real-time Price: $69.22 info
Change: -$16.79 (-20%) info
Market Cap: $7.576B info
CORT
Oct 20, 2026, 4:00 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $116.51
Real-time Price: $69.22 info
Change: -$47.29 (-41%) info
Market Cap: $7.576B info
CORT
Sep 18, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $114.90
Real-time Price: $69.22 info
Change: -$45.68 (-40%) info
Market Cap: $7.576B info